Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Size to Grow by USD 6.75 Billion

NEW YORK, March 31, 2022 / PRNewswire / – The Epidermal Growth Factor Receptor (EGFR) Inhibitors Market value is set to grow by USD 6.75 billionprogressing at a CAGR of 8.6% from 2021 to 2026, as per the latest report by Technavio.

Technavio has announced its latest market research report titled Epidermal Growth Factor Receptor (EGFR) Inhibitors Market by Indication and Geography – Forecast and Analysis 2022-2026

Resulting in YOY growth rate of 8.00% in 2022, read additional information about the market, Get FREE sample report.

Vendor Landscape

The epidermal growth factor receptor (EGFR) inhibitors market report also offers information on several market vendors, including Amgen Inc., Apollomics Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., and Takeda Pharmaceutical Co. Ltd. among others.

Moreover, the market is fragmented and the vendors are deploying growth strategies such as investing in R and D to compete in the market.

  • F. Hoffmann La Roche Ltd.- The company offers epidermal growth factor receptor that provides pharmaceuticals, solutions for diagnosis, personalized healthcare, wellness, and other segments. It is a public company headquartered in Switzerland. It is a global company generating USD 66,254.93 million in revenues and has around 100,000 employees. Its revenue from the global epidermal growth factor receptor (EGFR) inhibitors market contributes to its overall revenues along with its other offerings, but it is not a key revenue stream for the company.

Download Report to know about the market’s vendor landscape highlights with a comprehensive list of vendors and their offerings.

Latest Drivers & Trends of the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market

The US reports the highest number of cancer cases in the world. According to the Union for International Cancer Control (UICC), there were 19.1 million cancer cases in 2020, which resulted in 10 million deaths globally. In addition, the number of breast cancer cases increased by 24% in 2020 when compared with 2019. Moreover, the International Agency for Research on Cancer (IARC) has estimated that there will be around 29.4 million cancer cases by 2040, which will result in the death of 16.4 million people due to cancer. Despite the increasing prevalence of cancer, the market still witnesses a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as EGFR inhibitors for the treatment of cancer indications. Such factors are expected to support the market growth during the forecast period.

The high efficacy of EGFR inhibitors toward the treatment of various types of cancer has resulted in the recent approvals of various novel EGFR inhibitors such as IRESSA, TAGRISSO, ERBITUX, TARCEVA, and TYKERB. Various research institutes and pharmaceutical vendors in the market are conducting research on identifying the efficacy of EGFR inhibitors toward the treatment of various indications other than cancer. For instance, the studies in the early stages of clinical trials are helping in the identification of the use of EGFR inhibitors for the treatment of inflammatory diseases and monogenic diseases. New in-vitro research studies have shown that EGFR mutations are responsible for causing indications such as psoriasis, eczema, and atherosclerosis. Such factors are expected to positively impact the market growth in the forecast period.

Find additional information about various other market drivers & trends mentioned in our FREE sample report.

Key Market Segmentation

The epidermal growth factor receptor (EGFR) inhibitors market share growth by the lung cancer segment will be significant during the forecast period. The strong prevalence of the disease globally will result in an unmet need for therapeutics in the market, which will increase the demand for therapeutic options. This will result in the launch of novel drugs such as EGFR inhibitors for the treatment, thereby supporting the market growth in the coming years.

Request a FREE Sample of this report for more highlights into the market segments.

Our Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report Covers the Following Areas:

Regional Market Outlook

The market is segmented by Geography (North America, Europe, Asia, and ROW). 43% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for epidermal growth factor receptor (EGFR) inhibitors in North America. Market growth in this region will be faster than the growth of the market in Europe and Rest of World (ROW).

The increasing prevalence of various types of major cancer indications and heavy sales of approved therapeutics will facilitate the epidermal growth factor receptor (EGFR) inhibitors market growth in North America over the forecast period.

Download our FREE sample report for more key highlights on the regional market share of most of the above-mentioned countries.

Need More? Are You Looking for Information Not Covered in This Report?

  • Want to understand more about the various research methodology?

  • Evaluate a specific segment or region in detail

  • Identify key suppliers, customers, or other market players

  • Analyze market regulations

Tailor this report according to your needs. Get it done with our $ 1000 worth of free customization. Speak to Our Analyst Now!

Related Reports:

Global Urinary Drainage Bags Market: The global urinary drainage bags market size will grow by USD 141.88 million. This market report provides a detailed analysis of the market by type, usage, and geography. To get more exclusive research insights: Download Our FREE Sample Report

3D Cardiac Mapping Systems Market by Product and Geography – Forecast and Analysis 2022-2026: The 3D cardiac mapping systems market share is expected to increase by USD 444.5 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 8.36%. To get more exclusive research insights: Download Our FREE Sample Report

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 8.6%

Market growth 2022-2026

$ 6.75 billion

Market structure

Fragmented

YoY growth (%)

8.0

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 43%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Amgen Inc., Apollomics Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Checkpoint Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., and Takeda Pharmaceutical Co. Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,

Customization preview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Indication

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Technavio (PRNewsfoto / Technavio)

Technavio (PRNewsfoto / Technavio)

Cision

Cision

View original content to download multimedia: https: //www.prnewswire.com/news-releases/epidermal-growth-factor-receptor-egfr-inhibitors-market-size-to-grow-by-usd-6-75-billion –market-size-completive-analysis-industry-segments-share-and-forecast-to-2026–301513956.html

SOURCE Technavio

Leave a Comment